FII stake increase: Foreign Institutional Investors (FIIs) have increased their stake in Lincoln Pharma from 0.63 per cent in September 2022 to 2.59 per cent in September 2023.

Promoter holding increase: The promoter holding in Lincoln Pharma has also increased from 44.09 per cent in September 2022 to 50.53 per cent in September 2023.

In Q2FY23, the company continues to report record quarterly sales, EBITDA and PAT. Consolidated domestic and exports sales continued its growth trend, growing by 57 per cent and 53 per cent YoY.